Condition
Advanced Dedifferentiated Liposarcoma
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06498648Phase 1RecruitingPrimary
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
NCT05694871Phase 2Active Not RecruitingPrimary
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
NCT04967521Phase 3Active Not RecruitingPrimary
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
Showing all 3 trials